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Abstract 
 
The Total Synthesis of (±)-Cepharatine A 
 
Charles Aaron Seipp, M.A. 
The University of Texas at Austin, 2013 
 
Supervisor:  Philip Magnus 
 
The hasubanan alkaloid cepharatine A, was efficiently synthesized in 8 steps from 
commercially available starting materials in overall 16% yield. Highlighted in this 
synthesis, is a tandem phenolic alkylation – annulation which formed both a quaternary 
center as well as an unsaturated ring. This key step allowed for rapid construction of the 
core of the molecule. Subsequent reductive amination and acid catalyzed cyclization 
afforded the title compound. 
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Chapter 1:  The Hasubanan Alkaloids and Cepharatine A 
1.0 INTRODUCTION 
 
The hasubanan alkaloids are a class of natural compounds bearing close structural 
resemblance to the morphinan alkaloids (Figure 1).i 
 
 
 
 
 
 
 
Since the discovery of the first hasubanan alkaloid, hasubanonine, in 1951, dozens of additional 
compounds in this unique class of molecules have been discovered. i,ii This class of molecules 
remains interesting from both a chemical and a biological perspective. Chemically, these 
structures are very complex and are an attractive synthetic target because they are composed of a 
functionally dense tetracyclic ring system and a quaternary carbon center. Biologically, it was 
thought that the hasubanan alkaloids may have potent analgesic properties based their close 
structural similarities to the morphinoids alkaloids. As a result, much of the initial research into 
the discovery and the syntheses of these molecules first took place to explore their potential 
analgesic properties. As of this time, there have been no reported analgesic effects from any of 
the hasubanan alkaloids; however, it has been hypothesized that this may be due to the antipodal 
nature of the hasubanan alkaloids when compared to the morphinoids. That is, the hasubanan 
.  
Figure 1: A comparison of the structure of representative alkaloids from the morphinoids 
and the hasubanan alkaloids. 
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alkaloids and the morphinoids both have opposite absolute stereochemistry. This observation 
lead Schultz et. al. to propose that the unnatural enantiomers of the hasubanan alkaloids may 
show bioactivity.iii As the isolated compounds all existed as the “wrong” enantiomer, it is 
possible that the unnatural enantiomer may have the desired analgesic effects. 
 
 
1.1 CEPHARATINE A 
 
In 2011, Guan et. al. added to the list of known hasubanan alkaloids when he isolated a 
new series of hasubanan alkaloids, cepharatines A-D, from the plant Stephania cepharantha 
(Figure 2).iv  
 
 
 
 
 
 
 
This plant has been used in Chinese folk medicine for the treatment of gout, rheumatism, and 
edema by the Miao people, and because of this people wondered what constituents of the plant 
may have medicinal properties. Guan et. al. obtained a sample of the plant from the Guizhou 
Province in China, dried the sample, and powdered it. Extraction into ethanol followed by 
subsequent removal of solvent yielded a residue which was separated by column 
 
 
Figure 2: The structures of cepharatines A-D as isolated by Guan, 2012. 
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chromatography. Subsequent analysis of the pure fractions gave rise to four unique compounds, 
cepharatines A-D. A crystal structure of cepharatine A was obtained to confirm its structure. 
 From a synthetic standpoint, all four of these compounds were interesting targets. First 
and foremost, these compounds each have a densely functionalized tetracyclic ring system and a 
quaternary carbon center. Even with the current advances in synthetic chemistry, there is still no 
efficient way of generating the cores of these molecules. Secondly, the potential for analgesic 
properties warranted an investigation of these alkaloids. Finally, there has been no known 
synthesis of the unnatural enantiomer of the compound.  While all four structures were of interest 
to our laboratory group, it was ultimately decided to focus on cepharatine A as Guan et. al. had 
obtained a crystal structure of this molecule. The crystal structure provided unambiguous 
identification which gave us confidence to begin a synthetic effort towards its construction. 
 
 
1.2 THE BIOSYNTHESIS OF CEPHARATINE A 
 
 While the biosynthesis of the cepharatine alkaloids is still under investigation and a topic 
of much debate, they are commonly thought to arise from the common biosynthetic intermediate 
sinoacutine (Scheme 1).v,vi, vii,iv 
 
 
 
 
 
 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two molecules of L-tyrosine are transformed into dopamine and aldehyde 9. A Pictet-Spangler 
like enzymatic coupling of these two molecules gives rise to (S)-norcoclaurine. Enzymatic 
addition of another phenolic hydroxyl, and subsequent methylations yields (S)-reticuline. In the 
biosynthesis of the morphinoids, the stereochemistry of (S)-reticuline is inverted to (R)-reticuline 
prior to the oxidative coupling. In the case of the hasubanan alkaloids, the oxidative phenolic 
coupling proceeds on (S)-reticuline, giving rise to sinoacutine. This failure to “correct” the 
stereochemistry of (S)-reticuline is ultimately what gives rise to the antipodal stereochemistry of 
the hasubanan alkaloids. From here, it is proposed that sinoacutine undergoes the elimination of 
the C9- nitrogen bond, followed by demethylation of the methoxy group on the C ring. This 
 
 
Scheme 1: The proposed biosynthesis of cepharatine A from L-tyrosine. 
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allows the tautomerization of dienone 13 to the extremely reactive diketo species 14. 
Nucleophilic addition of the secondary amine, followed by a proton transfer step, yields 
cepharatine A. 
 
1.2 PREVIOUS SYNTHESIS 
 
 Due to the recent discovery of the cepharatines, few total syntheses have been published. 
Of note is Reisman et. al’s synthesis of (-)-cepharatine A, which utilized a novel Friedel crafts-
like addition to generate the core structure of the molecule (Scheme 2).viii 
 
 
 
 
 
 
 
 
 
 
Reisman began her synthesis by forming sulfinimine 17 through the reaction of bromophenol 15 
and N-tert-butanesulfinimine. The chirality of the sulfinimine allowed for the stereoselective 
addition of Grignard 18, generating dienone 19, and thus constructing both the A and C rings of 
cepharatine A. Next, a Stille coupling installed an unsaturated center that upon cleavage of the 
 
 
Scheme 2: Reisman et. al’s total synthesis of (-) cepharatine. The key Friedel-Crafts 
alkylation afforded the coupling of the A and C rings of cepharatine. 
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sulfinimide with aqueous HCl, underwent an intramolecular condensation. Subsequent reduction 
with sodium borohydride yielded dienone 21. While three rings of the tetracyclic ring system of 
were already installed, it was still necessary to couple the A and C rings. Instead an oxidative 
phenolic coupling analogous to the proposed biosynthetic pathway, a Friedel-Crafts alkylation 
afforded the desired bond formation. First, bromination of the arene provided a necessary 
blocking group that prevented the reaction from giving the undesired regioisomer. Next, TfOH 
deprotected the phenol, providing an electron rich arene nucleophilic enough to readily undergo 
addition to the enone yielding compound 22.  While all four rings were installed, the E ring was 
connected to the wrong carbon in the molecule, thus a rearrangement was necessary. Treatment 
of enone 22 with TBHP, Triton B, and SiO2 afforded enone 23, establishing the regiochemistry 
seen in cepharatine A. Reductive debromination, followed by formation of the C9-C10 olefin 
with PhI(OAc)2, afforded 3 in 10 steps in an overall 10% yield.   
Utilizing this general synthetic scheme, Reisman et. al. was also able to 
enantioselectively synthesize (-)-cepharatine C, D, as well as (-)-8-demethoxyrinanine. While 
both enantioselective and concise, no synthesis of the unnatural enantiomer of cepharatine A was 
produced. As the unnatural enantiomer potentially has analgesic properties, it would be 
worthwhile to synthesize it. Furthermore, while concise it can be argued that this synthesis is not 
ideal. One of the major detractions from this route is that the molecule is not kept in the correct 
oxidation state throughout the synthesis. There are many late stage oxidations and reductions 
needed to furnish the final product, adding steps and decreasing the overall yield. Thus, a total 
synthesis was envisioned that would not only be able to provide (+)-cepharatine A, but also 
would avoid these unnecessary late stage changes in oxidation state. 
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Chapter 2: The Synthetic Strategy 
2.0 THE OXIDATIVE PHENOLIC COUPLING 
 
In the biosynthesis of cepharatine A, Stephania Cepharanthia first forms the C-N bond in 
reticuline, and then undergoes an oxidative phenolic coupling. While this may seem an expedient 
way to synthesize this molecule, in practice this reaction is exceedingly difficult to reproduce 
synthetically. In many of the early syntheses of morphinoids this route was attempted; however, 
the yield of the key coupling was low at best (Scheme 3). ix,x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Barton’s MnO2 oxidation of reticuline to salutaridine proceeded in only 0.012% yield, while 
Kametani’s azo coupling was optimized at a 1.1% yield. Though it may be possible to find a 
  
 
 
Scheme 3: Two attempts in the total syntheses of morphinoids to harness the power of 
the phenolic oxidation. Both proceeded in poor yields. 
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reliable and high yielding way of performing this transformation it would be prudent to find an 
alternative route.  
Knowing that 3 shares a common core with morphine, we looked back at the phenolic 
alkylation strategy that Magnus et. al.  used to set the quaternary center of morphine. In the total 
synthesis of (±)-morphine and (-)-galanthamine, they were able to effect this overall 
transformation by swapping the order of the steps in the biosynthesis; by utilizing a Suzuki 
coupling to couple the A and C rings instead of an oxidative phenolic coupling, they were able to 
use a high-yielding phenolic alkylation to form the quaternary center (Scheme 4).xi 
 
 
 
 
 
 
 
 
 
 
 
 
 
The A and C rings of morphine were first installed utilizing a Suzuki coupling. Subsequent 
alkylation yielded acetal 29, which underwent a phenolic alkylation in the presence of CsF at 130 
 
Scheme 4: In Magnus et. al.’s synthesis of morphine, the key phenolic alkylation set not only 
the quaternary center but also the functional handles needed for generation of the rest of the 
codeine core. 
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ºC to give dienone 30. Next, Henry conditions yielded nitro alkene 31. From this phenolic 
alkylation and subsequent Henry reaction, many structural features were gained. First and 
foremost, the quaternary center was formed in high yield. Furthermore, the formation of the B 
ring was able to occur while also installing the nitro group which was later reduced in order to 
the amine in the E ring. Finally, upon removal of the acetal, the D ring would easily form via an 
intramolecular conjugate addition accelerated by the conformation of the molecule.  
 
2.1 RETROSYNTHESIS 
 
This methodology, while exceptionally efficient, needed to be modified slightly for the 
total synthesis of cepharatine A. After all, cepharatine has a different connectivity for the E ring, 
as well as no D ring and an olefin at C9-C10. We postulated that, if a methyl group was added to 
the bottom ring, we could modify this reaction to not only generate the quaternary center but also 
generate the B ring of cepharatine A, affording the requisite olefin. We reasoned that the initial 
phenolic alkylation would generate an acidic vinyl methyl group, which could subsequently be 
deprotonated by the CsF and nucleophilicly attack the proximal aldehyde (Scheme 5).   
 
 
 
 
 
 
 
 
 
Scheme 5: Hypothesized mechanism for the tandem phenolic alkylation – annulation planned 
for the generation of the quaternary center in the total synthesis of cepharatine A. 
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This tandem phenolic alkylation – annulation would generate three rings and set the 
quaternary center using a minimal number of steps. A synthesis designed around this key step 
was devised (Scheme 6).  
 
 
 
 
 
 
 
 
Retrosynthetically, a concise method to cepharatine A was envisioned. It was realized that biaryl 
32 could be easily obtained via a Suzuki coupling to quickly form the A and C rings of 
cepharatine. A simple alkylation utilizing ethyl vinyl ether would generate the functional handle 
needed to install both the B ring and the quaternary carbon center upon exposure to cesium 
fluoride to generate dienone 34. It was expected that this key step would proceed by first 
generating the quaternary center. This transformation would turn the aryl methyl group into a 
much more acidic beta vinylic methyl, allowing deprotonation by excess cesium fluoride and 
subsequent annulation.  Reductive amination of the protected aldehyde with methyl amine will 
afford dienone 35, which can be cyclized to 3 under acidic conditions.  
  
 
Scheme 6: The retrosynthesis of cepharatine A. 
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Chapter 3: The Total Synthesis of Cepharatine A 
 
3.0 THE INITIAL STEPS 
 
The synthesis of cepharatine A was started exclusively from isovanillin (Scheme 7).  
 
 
 
 
 
 
 
While both 27 and 37 are commercially available, isovanillin is an extremely inexpensive 
starting material that is readily available as a byproduct of the paper manufacturing process.  
Isovanillin (36) was regioselectively brominated using iron, bromine, and sodium acetate to give 
bromophenol 27 in 54% yield. It was also realized that through hydrogenolysis of the aldehyde, 
it would be possible to obtain the required methyl substituted phenol 37. Unfortunately, initial 
attempts at this transformation gave mixed results. Initially, 10% palladium on carbon in 
methanol with a catalytic amount of hydrochloric acid was attempted at atmospheric pressures. A 
yield of 44% was obtained, but this was not easily reproduced. Over the next several attempts, 
yields ranging from 0% to 60% were obtained. Varying the concentration of HCl, the solvent, the 
source of the acid (AcOH, HClO4), or utilizing Pearlman’s catalyst did little to influence the 
results. Furthermore, despite purification by silica plug, samples obtained by this methodology 
.  
Scheme 7: Isovanillin provided the starting material for both of 
the required phenols. 
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turned black and became unrecognizable by NMR presumably due to residual Pd/C. Thus an 
alternative method for this transformation was sought. Transfer hydrogenation utilizing 
anhydrous ammonium formate as a hydrogen source gave no observable product. In searching 
the literature, it was discovered that transfer hydrogenations occur readily utilizing triethyl silane 
and palladium chloride, presumably through a palladium-silane intermediate (Figure 3).xii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When applied to the isovanillin system, the desired phenol was obtained in an 83% yield. More 
importantly, the reaction was easily reproducible and scalable, giving ready access to the desired 
compound. With 37 in hand, the rest of the coupling partner was synthesized (Scheme 8).  
.  
 
Figure 3: Proposed catalytic cycle for the transfer hydrogenation of isovanillin in the 
presence of palladium (II) chloride and triethyl silane. 
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Phenol 37 was regioselectively brominated and sequentially protected using TBSCl to give 
compound 39, which underwent halogen – metal exchange with nBuLi, and reacted with 
triisopropyl borate to yield boroxime 40. Interestingly, the 1H- NMR of the trimer shows three 
distinct sets of peaks, each presumably corresponding to a different rotamer of the compound. 
Upon heating at 60 oC for an hour, the NMR coalesced into a single spectrum. 
 
3.1 THE SUZUKI COUPLING 
 
With the boroxine in hand, attempts were made to couple 27 and 40 to afford biaryl 41. 
(Scheme 9). 
 
 
 
  
 
 
 
 
Scheme 8: Generation of the boroxine trimer. 
 
 
Scheme 9: Suzuki coupling of the A and C rings. 
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Initial attempts revolved around the use of Pd(dppf)Cl2, in a dioxane/water mixture heated to 
reflux. Unfortunately, after several attempts not even trace product was observed by LCMS. In 
an attempt to grasp what the problem could be, a myriad of different conditions were attempted. 
In the Magnus et. al. synthesis of morphine and galanthamine, a Pd2(dba)3 / P(cyc)3 system was 
used to afford a very similar biaryl (Figure 4).  
 
 
 
 
 
 
 
 
Unfortunately, this reaction gave no product. The only thing isolable from the mixture were both 
starting materials, as well as significant amounts of protodeborylated trimer. In order to discount 
the possibility that the trimer or the isovanillin derivative were not good or contained impurities 
that would hinder a Suzuki reaction, two control reactions were undertaken (Scheme 10).  
 
 
 
 
 
.  
 
Figure 4: Comparison of the cepharatine biaryl (left) vs. 
previously synthesized biaryl (right). 
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Both control reactions showed generation of product by LCMS analysis. Thus, we were able to 
determine that the problem did not lay in the reagents (or some impurity present in them) but in 
the reaction conditions itself. 
When one compares the two structures of the desired biaryl, the only differences between 
the two is the presence of the methyl group and a methoxy group on the boroxime needed for 
cepharatine A. As electron donating substituents on the borate increase the rate of the Suzuki 
coupling, the methoxyl most likely increases the rate of reaction and does not play a role in our 
observed problems. Thus, the cause of the issues fall solely upon the addition of the methyl 
group. While one would not usually consider an additional methyl group a substantial amount of 
  
 
Scheme 10: Control reactions to make sure that (a) the 2-bromoisovanillin and (b) the 
boroxine trimer were both competent Suzuki coupling partners. 
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steric hindrance, it is well known that Suzuki reactions containing three or four substituents ortho 
to the coupling site proceed only sluggishly, if at all.xiii This is particularly true if there is a 
substituent ortho to the boronic acid.  In the case of the present Suzuki system, there are three 
ortho substituents to the coupling center. It was thus decided that more forcing conditions were 
needed if this reaction were to proceed in an appreciable yield. Initially, attempts were made to 
vary the base strength, as strong bases have been shown to help in the coupling of sterically 
hindered Suzuki reactions.15, xiii Unfortunately, K3PO4 was the strongest base able to be tolerated 
without seeing substantial degradation presumably due to negative interactions with the aromatic 
aldehyde. In and of itself, the usage of K3PO4 still generated none of the desired biaryl. Higher 
temperatures, different solvents, phase transfer catalysts, different ligands and metals were all 
attempted, each affording no detectable product. In order to try even more extreme conditions, it 
was decided to utilize a sealed tube so that high pressures and temperatures could be maintained. 
The reaction was thus performed in a sealed tube, utilizing DMSO / CH2Cl2 at 120 
oC, 
utilizing Pd(dppf)Cl2 as a palladium/ligand source. An 8% yield was obtained, along with 
significant amounts of observed protodeborylation. While a low yield of product, this provided 
useful data. First, more forcing conditions were in fact capable of producing the coupling. 
Secondly, it gave a pure sample of product, which allowed for quick qualitative determination of 
reaction efficacy by TLC. Other solvents were tried in order to improve the yield, including 1,2 
dimethoxy ethane, pure DMSO, as well as DMF, but none were able to improve upon the 8% 
yield displayed previously.  
In running these reactions, it was noticed that upon addition of the base, the 
bromoisovanillin would turn a canary yellow color. This was reversible upon addition of dilute 
acid and was thus hypothesized to be due to the deprotonation of the phenol. A literature search 
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was performed in order to find other examples of unprotected o-phenols being coupled in Suzuki 
reactions. Unfortunately, few examples were found, and those that had been performed worked 
mostly in poor yield, save a few isolated examples. It was hypothesized that the deprotonation of 
the o-phenol may be playing a role in the decreased reaction rate, and thus the phenol was 
summarily masked using an acetate (Figure 5). 
 
 
 
 
 
Subjecting acetate 44 to the Suzuki coupling reaction in DME gave the desired biaryl in 
29% yield. While the yield had been substantially increased, trouble deprotecting the acetate in 
the presence of the labile phenolic TBS group forced abandonment of this approach in favor of 
optimizing the reaction on the unprotected phenol.  
While further searching for potential solutions to overcome the problems associated with 
the steric bulk of our coupling partners, several reviews published by Buchwald et. al. were 
obtained where he advocated the use of bulky biarylphosphine ligands for the coupling of 
hindered biaryls (Figure 6).xiv 
 
 
 
 
 
 
Figure 5: Structure of the acetate protected phenol. 
  
Figure 6: Structure of two of the Buchwald Ligands, SPhos and XPhos. 
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Buchwald hypothesizes that the steric bulk of the ligand plays a substantial role in the observed 
reactivity. While it may seem counter intuitive that a bulky ligand would aid in the reaction of 
sterically hindered coupling partners, it is important to consider the role the bulk of the ligand 
plays. The bulky ligand makes it extremely unlikely that two ligands will be bound to the 
palladium. In fact, the bulk drastically increases the equilibrium of the metal-ligand complex so 
that it favors the mono-ligated species. The mono-ligated palladium complex is a 12 or 14 e- 
species (depending on the exact mode of binding of the ligand) and thus would be extremely 
reactive towards oxidative addition. This enables otherwise slow Suzuki couplings to proceed at 
drastically enhanced rates. In order to test out the Buchwald ligands, a Suzuki reaction utilizing 
Xphos and Pd(OAc)2 at 90 
0C in toluene was performed, netting an overall 23% product yield. 
This was the first time product had been obtained outsides of a sealed tube utilizing either DME 
or DMSO as solvent. Spurred on by these results, SPhos was also tried, giving an increased yield 
of 40%. 
 While the Suzuki coupling was proceeding in usable yields, we were determined to 
further optimize the reaction. A paper was found demonstrating that dimethyl carbonate could 
act as a competent reaction solvent for Suzuki coupling reactions.xv While their hypothesis that 
this solvent could afford couplings without the addition of metal was ultimately shown to be 
incorrect in a subsequent study of theirs, we thought that their data did in fact suggest that DMC 
could help to accelerate the coupling reaction. In initial tests utilizing a dimethyl carbonate / 
SPhos system, yields seemed to be drastically improved. When conditions were optimized (RT, 
24 hours), this coupling system gave yields upwards of 70%.  Unfortunately, no studies were 
performed as to determine why this drastic increase in yield was observed. 
 19 
  
3.2 THE PHENOLIC ALKYLATION – ANNULATION 
 
Next, the core of the molecule was to be generated. 41 was alkylated using ethyl vinyl 
ether and bromine to afford acetal 32 (Scheme 11).  
 
 
 
 
 
 
 
When heated with CsF at 130 °C, 32 yielded dienone 34 as a canary yellow solid. We 
hypothesized that the quaternary center would form first, followed by deprotonation of the newly 
generated beta vinylic methyl group to form the double bond (Scheme 12). 
 
 
 
 
 
 
 
 
 
 
Scheme 12: Synthesis of the quaternary center from biaryl 32. 
 
 
Scheme 11: Synthesis of acetal 32. 
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 While a mechanistic study was not performed, one could observe this two-step reaction taking 
place. Initially by TLC, one witnessed disappearance of the starting material to afford a colorless 
UV active spot that was more polar than the starting materials. Upon stirring for another two 
hours, this newly form spot disappeared, generating a new yellow spot of higher Rf. Overall, this 
key step proceeded in 76% yield and generated not only the quaternary center of 34 but also the 
B ring. The structure of the obtained compound was confirmed by x-ray crystallography (see 
spectral data). A large amount of complexity was generated from this simple reaction, giving us 
efficient access to the core of cepharatine. 
  
3.3 THE COMPLETION OF CEPHARATINE A 
 
 Next, acetal 34 was hydrolyzed to the aldehyde and reductively aminated with 
methylamine to give amine 35 (Scheme 13).  
 
 
 
 
 
 
 
 
 
 
 
Scheme 13: Reductive amination of the quaternary center to form primary amine 35. 
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This step also proved to be problematic, as initial attempts to isolate the unmasked aldehyde 
showed that it is extremely unstable to ambient conditions, almost completely decomposing 
during formation and isolation. Furthermore, the reductive amination of the aldehyde utilizing 
MeNH3Cl gave predominately dimer 48 as a product, further limiting the utility of this reaction 
(Figure 7). 
 
 
 
 
 
 
To complicate matters further, addition of unhindered basic amines to dienone 34 caused the 
starting material to turn a deep green and decompose into several unidentified byproducts by 
TLC. Due to this unexpected decomposition pathway, the amine HCl salt had to be used in this 
reaction. Utilizing the amine HCl salt in the acidic conditions required to break the acetal further 
reduced the nucleophilicity of the amine to the point where dimer 48 was the only product. Thus, 
in order to maximize the yield, it was necessary to break apart the acetal in situ to minimize 
decomposition of the aldehyde yet still provide a nucleophilic source of methylamine that was 
not so basic as to decompose the 34. Ultimately, Amberlyst 15 resin was utilized in order to 
generate the aldehyde in situ. The amberlyst was filtered off, leaving behind a neutral solution 
and a 52 fold excess of MeNH3Cl pre-dissolved in water was added. After stirring for 10 
minutes, triacetoxy borohydride was added to reduce the formed imine. The amine 35 was 
crudely purified by prep-TLC. In the biosynthesis of cepharatine A, it is thought that the amine is 
 
Figure 7: The dimeric product formed from the reductive 
amination of 34. 
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able to cyclize through reaction diketo intermediate 14. It was suspected that upon addition of 
aqueous HCl to 35, it may be possible to form a species analogous to the diketone intermediate. 
Thus, amine 35 was then refluxed in dilute hydrochloride acid to generate cepharatine A in 42% 
yield from the initial formation of the aldehyde (Scheme 14).  
 
  
 
 
 
 
 
 
Overall, (±) cepharatine A was synthesized in 8 steps from commercially available starting 
materials in an overall 16% yield. This was accomplished using a tandem intramolecular 
phenolic alkylation – annulation which proceeded in 76% yield. This methodology has been 
shown to provide exceedingly facile access to the core of these molecules, and we hope to 
expand upon the scope in the near future. 
 
 
 
 
 
 
 
Scheme 14: Synthesis of cepharatine A from amine 35. 
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Chapter 4: Experimental Conditions and Spectral Data 
4.0 GENERAL INFORMATION 
 
 All reagents were purified using standard laboratory methods unless otherwise noted.xvi 
Anhydrous solvents were prepared as follows: CH2Cl2 and THF were allowed to sit over sieves 
for 24 hours and then distilled under a nitrogen atmosphere. Other solvents were purified as 
noted in the experimental. All reactions were conducted under an argon atmosphere unless noted 
otherwise. 
 Reactions were monitored by thin layer chromatography using Merck 60 F254 glass-
backed silica gel plates. The plates were visualized using either 254 or 365 nm light, or 
developed using vanillin, ninhydrin, ceric ammonium molybdate, or p-anisaldehyde solution. 
Flash column chromatography was performed using EMD silica gel (particle size of 0.040-0.063 
).  
 Melting points were taken on a Thomas-Hoover capillary tube apparatus. Infrared 
spectra were recorded on a Thermo-Nicolet Avatar 360 FT-IR spectrophotometer. Samples were 
prepared as neat films on NaCl plates, unless otherwise indicated. 1H NMR spectra were 
recorded on a Varian spectrometer at 300 MHz or 500  
MHz in the indicated solvent and are reported in ppm and referenced internally to the residually 
protonated solvent. 13C NMR spectra were recorded on a Varian spectrometer at 75 MHz or 125 
MHz or 150 MHz in the solvent indicated and referenced internally to the residually protonated 
solvent. Mass spectra were obtained on a VG ZAB2E or a Finnigan TSQ70. 
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4.1 EXPERIMENTAL CONDITIONS AND COMPOUND DATA 
 
2-bromoisovanillin (27)xvii 
 
 
 
 
 
 
Br2 in 5 mL of acetic acid was added dropwise to a solution of isovanillin (4 g, 26.3 mmol), iron 
powder (.12 g, 2.14 mol), and sodium acetate (4.33 g, 52.76 mmol) in 24 mL of acetic acid. After 
all starting material was consumed as justged by TLC, the mixture was poured onto ice water. 
The precipitate was collected and washed with cold water. The crude material was recrystallized 
in EtOH to afford (3.27 g, 54%). 1H NMR (400 MHz, CDCl3) δ 10.28 (1H, s), 7.62 (1H, d, J = 
8.7), 6.96 (1H, d, J = 8.7), 6.09 (1H, s), 4.03 (3H, s) 
 
 
 
2-methoxy-5-methylphenol (37) xii 
 
 
 
 
 
Isovanillin (5 g, 0.032 mol), triethylsilane (12.6 mL, 0.079)was dissolved in 125 mL of EtOH. 
PdCl2 (50 mg, 0.282 mmol) was added to the flask in one portion. Reaction was monitored by 
TLC. Upon consumption of starting materials, reaction was concentrated under vacuum and 
purified by flash column chromatography (90:10 Hexanes:EtOAC) to afford 3.72 grams of 2 
 
 
 25 
(83%). 1H NMR (400 MHz, CDCl3) δ 6.75 (2H, m), 6.65 (1H, d, J = 7.2), 3.86 (3H, s), 2.26 (3H, 
s). 
 
 
4-bromo-2-methoxy-5-methylphenol (38)xviii 
 
 
 
To a solution of isocreosol (10 g, 72 mmol) in AcOH (144 mL) was added N-bromosuccinimide 
(13.13 g, 74 mmol) in AcOH (343 mL) dropwise over one hour. The reaction was allowed to run 
for 4 hours. The mixture was concentrated in vacuo to roughly one third of the original volume 
before ice was added and the solution was neutralized with 6 M NaOH, causing the product to 
precipitate. The product was extracted with CH2Cl2 and subsequently purified by flash column 
chromatography (70:30 Hexanes:EtOAc) to afford the product as a white solid (15.1 g, 97% 
yield). 1H NMR (400 MHz, CDCl3) δ 7.01 (1H, s), 6.83 (1H, s), 5.47 (1H, s), 3.88 (3H, s), 2.31 
(3H, s). 
 
(4-bromo-2-methoxy-5-methylphenoxy)(tert-butyl)dimethylsilane (39) 
 
 
 
 
 
 
To a solution of methyl phenol (1) (50g, 0.23 mol) in 500 mL dichloromethane was added 
imidazole (31.31g, 0.36 mol). The solution was stirred for 15 minutes before tert-
butyldimethylsilyl chloride (38.1g, 0.25 mol) was added in one portion. After all starting 
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material was consumed, as judged by TLC, the reaction was poured onto saturated aqueous 
ammonium chloride. The dichloromethane was separated, and the aqueous layer was extracted 
with ethyl acetate (3X, 50 mL aliquots). The organic phases were combined, and solvent was 
removed in vacuo to yield a viscous yellow oil. Purification by flash column chromatography 
(SiO2, 30:70 EtOAc:hexanes, slow gradient from pure hexanes) yielded 2  as a clear viscous 
liquid (72.16 g, 94.6%). 1H NMR (400 MHz, CDCl3) δ 6.96 (1H, s), 6.72 (3H, s), 3.77 (1H, s), 
2.27 (3H, s), 0.99 (9H, s), 0.14 (6H, s). 13C NMR (100 MHz, CDCl3) δ149.7, 144.3, 129.9, 
123.0, 116.1, 115.5, 55.8, 25.8, 22.1, 18.5, -4.5 HRMS calcd. for C14H23BrO2Si: 331.07235 (M+) 
found 331.07212 
 
2,4,6-tris(4-((tert-butyldimethylsilyl)oxy)-2-methoxy-5-methylphenyl)-1,3,5,2,4,6-
trioxatriborinane (40)xvii 
 
 
 
 
 
 
To a -78 °C solution of silane 2 (20 g, 0.06 mol) in 100 mL THF was added nBuLi(2.4 M, 28.8 
mL) dropwise. The solution was stirred for 30 minutes. Triisopropyl borate (36.3 mL, 0.193 mol) 
was added dropwise and the solution was allowed to warm to room temperature and stirred over 
night. The reaction was quenched with aqueous 10% sodium bisulfate, extracted three times with 
ethyl acetate (25 mL), and dried with Na2SO4. The solvent was removed in vacuo and the white 
solid was purified by flash column chromatography (90:10 Hexanes:EtOAc) to give 3 as a white 
solid (7.15 g, 85.2 %). IR (thin film): 3226.5, 2957.6, 2927.2, 2857.8, 1558.8, 1512.0, 1465.0, 
1339.1, 1275.3, 1206.1, 1151.3, 1109.0, 1053.5 1H NMR (400 MHz, CDCl3) δ 7.75 (1H, s), 6.75 
(1H, s), 3.84 (3H, s), 2.73 (3H, s), 1.02 (9H, s), 0.20 (6H, s). 13C NMR (100 MHz, CDCl3) δ 
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153.0, 152.8, 128.2, 125.0, 59.8, 30.3, 30.3, 26.5, 23.1, 0.0. HRMS calcd. for C42H70B11O9Si3: 
835.4607 (M+1) found 835.4619 
 
 
 
 
 
4'-((tert-butyldimethylsilyl)oxy)-6-hydroxy-5,5'-dimethoxy-2'-methyl-[1,1'-biphenyl]-2-
carbaldehyde (41) (xv,xix)  
 
 
 
 
 
 
 
 
 
 
 
To 100 mL of dimethyl carbonate is added 2-bromo-3-hydroxy-4-methoxybenzaldehyde (3 g, 
13.0 mmol), 3 (5.46 g, 19.6 mmol), Pd(OAc)2 (60 mg, 0.27 mmol ), SPHOS (216 mg, 0.53 
mmol), and K3PO4 (5.4 g, 25.4 mmol). The solution was allowed to stir for 48 hours. The solvent 
was removed in vacuo and the biaryl was washed with saturated NH4Cl  then extracted with 
EtOAc (3X, 25 mL). The EtOAc was removed in vacuo and the crude product was purified by 
flash column chromatography (30:70 EtOAc:Hexanes) to afford 4 (3.67 g, 70%) as a pale brown 
solid. IR (thin film): 3289.3, 2937.9, 2855.0, 1670.0, 1584.6, 1514.9, 1472.7, 1441.0, 1387.9, 
1326.1, 1269.9, 1093.9, 1028.6 1H NMR (400 MHz, CDCl3) δ 9.52 (1H, s), 7.66 (1H, d, J = 8.4), 
7.00 (1H, d, J = 8.4), 6.81 (1H, s), 6.66 (1H, s), 5.53 (1H, s), 4.01 (3H, s), 3.74 (3H, s), 1.98 (3H, 
s), 1.014 (9H, s), 0.20 (6H, s). 13C NMR (100 MHz, CDCl3) δ 190.7, 150.3, 148.0, 144.2, 141.7, 
130.5, 129.1, 127.4, 123.2, 121.8, 119.5, 113.6, 108.9, 55.3, 54.7, 24.8, 18.2, 17.6, -5.4. HRMS 
calcd. for C22H31O5Si: 403.19353 (M+1) found 403.19322 
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6-(2-bromo-1-ethoxyethoxy)-4'-((tert-butyldimethylsilyl)oxy)-5,5'-dimethoxy-
2'-methyl-[1,1'-biphenyl]-2-carbaldehyde (32)  
 
 
 
 
 
 
 
 
 
 
To a solution of Br2 (.65 mL, 0.012 mol) in CH2Cl2 (40 mL) at 0°C was added 1.3 mL ethyl vinyl 
ether (1.3 mL, 0.014 mol) drop wise until the solution turned colorless. The solution was allowed 
to stir for 30 minutes before Hunig’s base (3.0 mL, 0.017 mol) and 4 (2.14 g, 0.005 mol) were 
added. The solution was allowed to stir until judged complete by TLC. The reaction mixture was 
poured onto NaHCO3, extracted with CH2Cl2 (3x, 10 mL), and dried (Na2SO4). The solvent was 
removed in vacuo and the residual oil was purified via column chromatography (SiO2, 30:70 
EtOAc:hexanes, slow gradient from pure hexanes) to afford a clear liquid (2.62 g, 89.1 % yield). 
IR (thin film): 2930.4, 2856.7, 1685.6, 1586.1, 1514.7, 1472.4, 1438.3, 1385.8, 1327.9, 1301.2, 
1250.2, 1212.6, 1096.2, 931.4  1H NMR (400 MHz, CDCl3) δ 9.48 (1H, s), 7.86 (1H, d, J = 8.8), 
7.05 (1H, d, J = 8.8), 6.79 (1H, s), 6.70 (1H, s), 6.67 (1H, s), 4.9 (1H, m), 3.97 (3H, s), 3.74 (3H, 
s), 3.5 (1H, bm), 3.1 (3H, bm), 1.98 (3H, s), 1.07 (2H, m), 1.03 (9H, s), 0.18 (6H, s). 13C NMR 
(100 MHz, CDCl3) δ 191.3, 191.3, 157.7, 157.7, 148.8, 148.7, 145.2, 140.3, 130.1, 130.0, 128.5, 
128.5, 125.2, 125.2, 125.1, 125.0, 122.7, 122.5, 115.1, 115.0, 111.3, 111.2, 104.1, 104.0, 64.5, 
64.0, 56.1, 56.1, 55.9, 55.7, 31.9, 31.7, 31.6, 25.8, 22.7, 19.4, 19.4, 18.6, 15.1, 15.1, -4.5, -4.5, -
4.6 . HRMS calcd. for C26H38BrO6Si: 553.16155 (M+1) found 553.16118 
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6-ethoxy-3,8-dimethoxy-5,6-dihydro-2H-naphtho[1,2-de]chromen-2-one (34) 
 
 
 
 
 
 
 
 
 
A solution of 5 (1 g, 1.8 mmol) under argon in DMF (40 mL) was heated to 80 °C while CsF 
(1.2 g, 7.9 mmol) was thoroughly flame dried under vacuum. The CsF was quickly added in one 
portion and the temperature of the reaction mixture was immediately raised to 130 °C. A deep 
red color was observed immediately upon addition of CsF. Upon completion (as judged by TLC) 
the mixture was poured onto sodium bicarbonate, extracted into EtOAc (3x, 15 mL), and dried 
(Na2SO4), and concentrated in vacuo. 6 was isolated via flash column chromatography (30:70 
EtOAc:Hexanes), to afford 560 mg (76%) of canary yellow solid. MP (Hexanes:EtOAC) 147-
150 °C. IR (thin film): 2974.1, 2932.1, 1653.8, 1627.2,, 1602.8, 1554.5, 1499.0, 1450.5, 1438.8, 
1408.2, 1355.8, 1267.5, 1205.0, 1174.5, 1109.3, 1048.6, 998.9, 973.8  1H NMR (400 MHz, 
CDCl3) δ 7.25-6.80 (2H, m), 6.70-6.60 (2H, m), 6.43 (1H, d, J = 9.0), 5.62 (.5H, m), 5.13 (.5H, 
m), 4.25 (.5H, m), 4.03 (.5H, m), 3.90 (3H, s), 3.62 (3H, s), 2.40 (.5 H, m), 2.20-2.00 (1.5 H, m), 
1.65 (.5H, s), 1.29 (1.5H, t,  J = 8.0),  1.18 (1.5H, t, J = 8.0). 13C NMR (100 MHz, CDCl3): 
δ181.7, 181.4, 161.7, 161.3, 152.8, 152.3, 151.5, 151.4, 142.5, 141.6, 132.7, 132.2, 128.5, 128.4, 
124.5, 124.5, 124.4, 124.3, 123.8, 123.7, 123.6, 123.1, 120.7, 118.8, 111.3, 111.1, 102.0, 101.8, 
66.1, 65.0, 56.6, 56.3, 56.0, 55.9, 55.6, 43.0, 43.7, 15.8, 15.4. HRMS calcd. for C20H20NaO5: 
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363.12029 (M+Na) found 363.12034
 
Crystal data and structure refinement for 34. 
Empirical formula  C20 H20 O5 
Formula weight  340.36 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P-1 
  Unit cell dimensions a = 7.0150(6) Å  
 b = 10.4826(7) Å  
 c = 23.8587(19) Å  
Volume 1662.5(2) Å3 
Z 4 
Density (calculated) 1.360 Mg/m3 
Absorption coefficient 0.097 mm-1 
F(000) 720 
Crystal size 0.22 x 0.10 x 0.04 mm 
Theta range for data collection 3.03 to 25.00°. 
Index ranges -8<=h<=8, -12<=k<=12, -8<=l<=28 
Reflections collected 5854 
Independent reflections 5854 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
 31 
Max. and min. transmission 1.00 and 0.451 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5854 / 0 / 458 
Goodness-of-fit on F2 1.502 
Final R indices [I>2sigma(I)] R1 = 0.1329, wR2 = 0.2981 
R indices (all data) R1 = 0.1845, wR2 = 0.3223 
Largest diff. peak and hole 0.650 and -0.661 e.Å-3 
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 Table 1.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) 
for 1.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________
__  
 x y z U(eq) 
______________________________________________________________________________
__   
C1 5086(10) -1964(7) 5389(3) 22(2) 
C2 3275(10) -1927(7) 5771(3) 19(2) 
C3 3754(10) -2054(6) 6409(3) 18(2) 
C4 5288(11) -3396(7) 6564(3) 24(2) 
C5 4730(10) -4512(7) 6745(3) 21(2) 
C6 2600(10) -4470(7) 6849(3) 22(2) 
C7 1252(11) -3131(7) 6900(3) 24(2) 
C8 1875(10) -1999(7) 6765(3) 22(2) 
C9 845(11) -771(8) 6972(3) 28(2) 
C10 1734(11) 230(7) 6977(3) 23(2) 
C11 3621(10) 228(7) 6699(3) 21(2) 
C12 4420(11) 1299(7) 6655(3) 26(2) 
C13 6119(11) 1331(7) 6317(3) 26(2) 
C14 6935(11) 319(7) 5993(3) 24(2) 
C15 6084(10) -755(7) 6033(3) 20(2) 
C16 4569(10) -872(7) 6418(3) 22(2) 
C17 7375(10) -3353(7) 4806(3) 23(2) 
C18 7416(11) -4585(7) 4545(3) 32(2) 
C19 8034(10) -5913(7) 6801(3) 28(2) 
C20 9259(12) 1455(7) 5525(3) 30(2) 
C21 121(10) -1676(7) 9626(3) 21(2) 
C22 -1677(10) -1359(7) 9244(3) 21(2) 
C23 -1065(10) -1097(7) 8599(3) 20(2) 
C24 489(10) -2370(7) 8470(3) 20(2) 
C25 -70(10) -3347(7) 8292(3) 17(2) 
C26 -2157(10) -3190(7) 8140(3) 21(2) 
C27 -3436(10) -1819(7) 8079(3) 24(2) 
C28 -2894(10) -783(7) 8238(3) 22(2) 
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C29 -3898(11) 586(7) 8031(3) 24(2) 
C30 -3007(10) 1577(7) 8010(3) 24(2) 
C31 -1077(10) 1362(7) 8280(3) 21(2) 
C32 -261(11) 2416(7) 8315(3) 24(2) 
C33 1378(11) 2213(7) 8658(3) 27(2) 
C34 2076(10) 1004(7) 9004(3) 21(2) 
C35 1254(10) -53(7) 8981(3) 18(2) 
C36 -237(10) 109(7) 8588(3) 21(2) 
C37 2274(10) -3478(7) 10221(3) 23(2) 
C38 2338(11) -4911(7) 10474(3) 33(2) 
C39 3252(10) -4756(7) 8278(4) 29(2) 
C40 4368(11) 1808(7) 9482(3) 29(2) 
O1 6739(7) -1696(5) 5671(2) 22(1) 
O2 5776(7) -3222(4) 5232(2) 22(1) 
O3 5947(7) -5806(5) 6855(2) 24(1) 
O4 2057(7) -5517(5) 6945(2) 32(1) 
O5 8451(7) 313(4) 5607(2) 26(1) 
O6 1804(7) -1233(4) 9355(2) 22(1) 
O7 792(7) -3066(4) 9790(2) 21(1) 
O8 1165(7) -4582(4) 8210(2) 24(1) 
O9 -2672(7) -4146(5) 8014(2) 32(1) 
O10 3567(7) 718(5) 9404(2) 25(1) 
______________________________________________________________________________
__ 
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 Table 2.   Bond lengths [Å] and angles [°] for  1. 
_____________________________________________________  
C1-O2  1.376(8) 
C1-O1  1.485(8) 
C1-C2  1.515(9) 
C1-H1  1.00 
C2-C3  1.556(9) 
C2-H2A  0.99 
C2-H2B  0.99 
C3-C16  1.506(9) 
C3-C4  1.518(9) 
C3-C8  1.520(9) 
C4-C5  1.336(9) 
C4-H4  0.95 
C5-O3  1.379(8) 
C5-C6  1.490(9) 
C6-O4  1.244(8) 
C6-C7  1.475(10) 
C7-C8  1.362(10) 
C7-H7  0.95 
C8-C9  1.437(10) 
C9-C10  1.365(10) 
C9-H9  0.95 
C10-C11  1.446(10) 
C10-H10  0.95 
C11-C12  1.376(10) 
C11-C16  1.410(10) 
C12-C13  1.407(10) 
C12-H12  0.95 
C13-C14  1.387(10) 
C13-H13  0.95 
C14-O5  1.366(8) 
C14-C15  1.403(9) 
C15-O1  1.381(8) 
C15-C16  1.383(10) 
C17-O2  1.463(8) 
C17-C18  1.513(9) 
C17-H17A  0.99 
C17-H17B  0.99 
C18-H18A  0.98 
C18-H18B  0.98 
C18-H18C  0.98 
C19-O3  1.437(8) 
C19-H19A  0.98 
C19-H19B  0.98 
C19-H19C  0.98 
C20-O5  1.445(7) 
C20-H20A  0.98 
C20-H20B  0.98 
C20-H20C  0.98 
C21-O7  1.397(8) 
C21-O6  1.467(7) 
C21-C22  1.526(9) 
C21-H21  1.00 
C22-C23  1.575(10) 
C22-H22A  0.99 
C22-H22B  0.99 
C23-C28  1.515(9) 
C23-C36  1.528(9) 
C23-C24  1.530(9) 
C24-C25  1.328(9) 
C24-H24  0.95 
C25-O8  1.377(8) 
C25-C26  1.486(9) 
C26-O9  1.239(8) 
C26-C27  1.456(10) 
C27-C28  1.359(9) 
C27-H27  0.95 
C28-C29  1.430(10) 
C29-C30  1.348(9) 
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C29-H29  0.95 
C30-C31  1.477(10) 
C30-H30  0.95 
C31-C36  1.385(10) 
C31-C32  1.395(9) 
C32-C33  1.397(10) 
C32-H32  0.95 
C33-C34  1.375(10) 
C33-H33  0.95 
C34-C35  1.394(9) 
C34-O10  1.394(8) 
C35-O6  1.378(8) 
C35-C36  1.401(10) 
C37-O7  1.432(8) 
 
C37-C38  1.517(10) 
C37-H37A  0.99 
C37-H37B  0.99 
C38-H38A  0.98 
C38-H38B  0.98 
C38-H38C  0.98 
C39-O8  1.438(8) 
C39-H39A  0.98 
C39-H39B  0.98 
C39-H39C  0.98 
C40-O10  1.448(7) 
C40-H40A  0.98 
C40-H40B  0.98 
C40-H40C  0.98 
O2-C1-O1 107.5(5) 
O2-C1-C2 108.9(6) 
O1-C1-C2 113.1(5) 
O2-C1-H1 109.1 
O1-C1-H1 109.1 
C2-C1-H1 109.1 
C1-C2-C3 112.5(6) 
C1-C2-H2A 109.1 
C3-C2-H2A 109.1 
C1-C2-H2B 109.1 
C3-C2-H2B 109.1 
H2A-C2-H2B 107.8 
C16-C3-C4 112.9(6) 
C16-C3-C8 113.7(6) 
C4-C3-C8 110.5(6) 
C16-C3-C2 102.4(5) 
C4-C3-C2 107.0(5) 
C8-C3-C2 109.7(5) 
C5-C4-C3 120.8(6) 
 
Table 2 Continued 
C5-C4-H4 119.6 
C3-C4-H4 119.6 
C4-C5-O3 127.0(6) 
C4-C5-C6 121.5(6) 
O3-C5-C6 111.5(6) 
O4-C6-C7 122.9(6) 
O4-C6-C5 121.4(6) 
C7-C6-C5 115.3(6) 
C8-C7-C6 121.2(6) 
C8-C7-H7 119.4 
C6-C7-H7 119.4 
C7-C8-C9 121.5(7) 
C7-C8-C3 119.2(6) 
C9-C8-C3 119.2(6) 
C10-C9-C8 121.4(7) 
C10-C9-H9 119.3 
C8-C9-H9 119.3 
C9-C10-C11 122.9(7) 
C9-C10-H10 118.6 
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C11-C10-H10 118.6 
C12-C11-C16 119.2(7) 
 
C12-C11-C10 122.8(6) 
C16-C11-C10 117.6(6) 
C11-C12-C13 120.9(7) 
C11-C12-H12 119.5 
C13-C12-H12 119.5 
C14-C13-C12 120.0(7) 
C14-C13-H13 120.0 
C12-C13-H13 120.0 
O5-C14-C13 125.1(7) 
O5-C14-C15 116.4(6) 
C13-C14-C15 118.4(7) 
O1-C15-C16 119.3(6) 
O1-C15-C14 119.1(6) 
C16-C15-C14 121.5(7) 
C15-C16-C11 118.8(6) 
C15-C16-C3 116.2(6) 
C11-C16-C3 123.5(6) 
O2-C17-C18 106.2(5) 
O2-C17-H17A 110.5 
C18-C17-H17A 110.5 
O2-C17-H17B 110.5 
C18-C17-H17B 110.5 
H17A-C17-H17B 108.7 
C17-C18-H18A 109.5 
C17-C18-H18B 109.5 
H18A-C18-H18B 109.5 
C17-C18-H18C 109.5 
H18A-C18-H18C 109.5 
H18B-C18-H18C 109.5 
O3-C19-H19A 109.5 
O3-C19-H19B 109.5 
H19A-C19-H19B 109.5 
O3-C19-H19C 109.5 
H19A-C19-H19C 109.5 
H19B-C19-H19C 109.5 
O5-C20-H20A 109.5 
O5-C20-H20B 109.5 
H20A-C20-H20B 109.5 
O5-C20-H20C 109.5 
H20A-C20-H20C 109.5 
H20B-C20-H20C 109.5 
O7-C21-O6 107.2(5) 
O7-C21-C22 109.1(6) 
O6-C21-C22 114.2(6) 
O7-C21-H21 108.7 
O6-C21-H21 108.7 
C22-C21-H21 108.7 
C21-C22-C23 110.9(6) 
C21-C22-H22A 109.5 
C23-C22-H22A 109.5 
C21-C22-H22B 109.5 
C23-C22-H22B 109.5 
H22A-C22-H22B 108.0 
C28-C23-C36 113.1(6) 
C28-C23-C24 111.6(6) 
C36-C23-C24 113.8(6) 
C28-C23-C22 109.0(6) 
C36-C23-C22 101.4(5) 
C24-C23-C22 107.2(5) 
C25-C24-C23 120.3(6) 
C25-C24-H24 119.8 
C23-C24-H24 119.8 
C24-C25-O8 125.6(6) 
C24-C25-C26 122.2(6) 
O8-C25-C26 112.2(5) 
O9-C26-C27 123.4(6) 
O9-C26-C25 121.1(6) 
C27-C26-C25 115.0(6) 
C28-C27-C26 123.2(7) 
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Table 2 Continued 
C28-C27-H27 118.4 
C26-C27-H27 118.4 
C27-C28-C29 121.5(7) 
C27-C28-C23 118.7(6) 
C29-C28-C23 119.6(6) 
C30-C29-C28 121.7(7) 
C30-C29-H29 119.2 
C28-C29-H29 119.2 
C29-C30-C31 122.2(7) 
C29-C30-H30 118.9 
C31-C30-H30 118.9 
C36-C31-C32 119.2(7) 
C36-C31-C30 117.6(6) 
C32-C31-C30 122.3(7) 
C31-C32-C33 120.4(7) 
C31-C32-H32 119.8 
C33-C32-H32 119.8 
C34-C33-C32 119.8(6) 
C34-C33-H33 120.1 
C32-C33-H33 120.1 
C33-C34-C35 120.3(6) 
C33-C34-O10 125.4(6) 
C35-C34-O10 114.3(6) 
O6-C35-C34 121.5(6) 
O6-C35-C36 119.0(6) 
C34-C35-C36 119.5(6) 
C31-C36-C35 120.1(6) 
C31-C36-C23 123.5(6) 
C35-C36-C23 115.7(6) 
O7-C37-C38 106.7(5) 
 
 
O7-C37-H37A 110.4 
C38-C37-H37A 110.4 
O7-C37-H37B 110.4 
C38-C37-H37B 110.4 
H37A-C37-H37B 108.6 
C37-C38-H38A 109.5 
C37-C38-H38B 109.5 
H38A-C38-H38B 109.5 
C37-C38-H38C 109.5 
H38A-C38-H38C 109.5 
H38B-C38-H38C 109.5 
O8-C39-H39A 109.5 
O8-C39-H39B 109.5 
H39A-C39-H39B 109.5 
O8-C39-H39C 109.5 
H39A-C39-H39C 109.5 
H39B-C39-H39C 109.5 
O10-C40-H40A 109.5 
O10-C40-H40B 109.5 
H40A-C40-H40B 109.5 
O10-C40-H40C 109.5 
H40A-C40-H40C 109.5 
H40B-C40-H40C 109.5 
C15-O1-C1 112.7(5) 
C1-O2-C17 114.7(5) 
C5-O3-C19 114.5(5) 
C14-O5-C20 117.6(5) 
C35-O6-C21 113.8(5) 
C21-O7-C37 114.4(5) 
C25-O8-C39 115.8(5) 
C34-O10-C40 117.0(5) 
_____________________________________________________________  
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 Table 3.   Anisotropic displacement parameters  (Å2x 103) for 1.  The anisotropic 
displacement factor exponent takes the form:  - 2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C1 24(4)  22(4) 23(4)  -7(3) -1(3)  -10(3) 
C2 18(4)  16(4) 26(4)  -8(3) 1(3)  -5(3) 
C3 11(4)  11(3) 34(4)  -10(3) 0(3)  -4(3) 
C4 17(4)  24(4) 31(4)  -1(3) -3(3)  -9(3) 
C5 9(4)  14(4) 38(5)  -3(3) -3(3)  -2(3) 
C6 19(4)  24(4) 28(4)  -4(3) 6(3)  -18(3) 
C7 13(4)  32(5) 27(4)  -6(3) -2(3)  -4(3) 
C8 10(4)  21(4) 29(4)  -1(3) 0(3)  2(3) 
C9 20(4)  32(5) 28(5)  -3(4) -3(3)  -1(4) 
C10 22(4)  19(4) 22(4)  -7(3) 3(3)  4(3) 
C11 14(4)  15(4) 30(4)  -5(3) -6(3)  3(3) 
C12 25(4)  21(4) 30(5)  -13(3) -5(3)  4(4) 
C13 30(4)  12(4) 38(5)  -2(3) -13(4)  -8(3) 
C14 19(4)  24(4) 32(5)  -9(4) 0(3)  -6(3) 
C15 22(4)  11(4) 27(4)  -2(3) -3(3)  -7(3) 
C16 18(4)  20(4) 28(4)  -3(3) -5(3)  -6(3) 
C17 15(4)  27(4) 33(4)  -11(3) 4(3)  -14(3) 
C18 15(4)  36(5) 54(6)  -25(4) 14(4)  -14(4) 
C19 13(4)  16(4) 56(6)  -3(4) -5(3)  -4(3) 
C20 35(5)  21(4) 42(5)  -2(4) -6(4)  -22(4) 
C21 14(4)  23(4) 31(4)  -5(3) 7(3)  -14(3) 
C22 17(4)  26(4) 20(4)  0(3) -4(3)  -9(3) 
C23 10(4)  16(4) 34(5)  -7(3) -6(3)  1(3) 
C24 15(4)  25(4) 23(4)  -3(3) 5(3)  -14(3) 
C25 10(4)  21(4) 23(4)  -4(3) -2(3)  -9(3) 
C26 10(4)  30(4) 25(4)  -6(3) 3(3)  -7(3) 
C27 12(4)  37(5) 26(4)  -2(4) -3(3)  -12(4) 
C28 11(4)  25(4) 30(4)  -7(3) 4(3)  -2(3) 
C29 15(4)  28(4) 29(4)  -5(3) 1(3)  -6(3) 
C30 20(4)  23(4) 25(4)  -2(3) 1(3)  -2(3) 
C31 18(4)  21(4) 27(4)  -9(3) 1(3)  -9(3) 
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Table 3 Continued 
C32 25(4)  18(4) 31(4)  2(3) -1(3)  -11(3) 
C33 28(4)  22(4) 37(5)  -9(4) 10(4)  -18(4) 
C34 17(4)  22(4) 28(4)  -6(3) -1(3)  -12(3) 
C35 20(4)  17(4) 21(4)  0(3) -1(3)  -11(3) 
C36 20(4)  11(4) 34(5)  -11(3) 6(3)  -6(3) 
C37 23(4)  30(4) 25(4)  -3(3) -4(3)  -21(4) 
C38 24(4)  28(4) 46(5)  7(4) -7(4)  -13(4) 
C39 8(4)  23(4) 55(6)  -1(4) 0(3)  -5(3) 
C40 33(5)  23(4) 39(5)  -12(4) 3(4)  -19(4) 
O1 16(3)  24(3) 32(3)  -8(2) -3(2)  -14(2) 
O2 17(3)  18(3) 33(3)  -8(2) 7(2)  -7(2) 
O3 15(3)  19(3) 45(3)  -3(2) -3(2)  -14(2) 
O4 25(3)  34(3) 45(3)  -15(3) 6(2)  -18(3) 
O5 26(3)  15(3) 41(3)  -5(2) 0(2)  -16(2) 
O6 13(3)  22(3) 34(3)  3(2) 1(2)  -13(2) 
O7 21(3)  14(3) 30(3)  3(2) -5(2)  -11(2) 
O8 13(3)  19(3) 41(3)  -8(2) 3(2)  -6(2) 
O9 23(3)  36(3) 42(3)  -6(3) -2(2)  -17(3) 
O10 20(3)  25(3) 36(3)  -8(2) -1(2)  -16(2) 
______________________________________________________________________________ 
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 Table 4.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 1. 
______________________________________________________________________________
__  
 x  y  z  U(eq) 
______________________________________________________________________________
__  
  
H1 4699 -1283 5042 26 
H2A 2727 -2672 5716 23 
H2B 2246 -1072 5658 23 
H4 6661 -3443 6532 28 
H7 -75 -3057 7030 29 
H9 -483 -652 7108 34 
H10 1086 960 7172 28 
H12 3816 2026 6856 32 
H13 6708 2047 6311 31 
H17A 8662 -3465 4985 27 
H17B 7113 -2545 4512 27 
H18A 7499 -5351 4846 49 
H18B 8574 -4787 4291 49 
H18C 6201 -4414 4328 49 
H19A 8333 -5535 6414 43 
H19B 8792 -6861 6878 43 
H19C 8402 -5416 7073 43 
H20A 8192 2280 5420 45 
H20B 10266 1356 5221 45 
H20C 9868 1505 5878 45 
H21 -295 -1238 9972 26 
H22A -2688 -554 9343 25 
H22B -2275 -2122 9307 25 
H24 1859 -2462 8516 24 
H27 -4714 -1639 7921 29 
H29 -5228 802 7906 29 
H30 -3642 2443 7814 28 
H32 -824 3278 8105 29 
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Table 4 Continued 
H33 2009 2907 8653 32 
H37A 1926 -2885 10517 27 
H37B 3584 -3435 10054 27 
H38A 1058 -4930 10657 49 
H38B 3394 -5255 10756 49 
H38C 2603 -5475 10172 49 
H39A 3516 -4747 8676 43 
H39B 3651 -4023 8038 43 
H39C 4010 -5617 8166 43 
H40A 5055 2077 9134 43 
H40B 5308 1509 9797 43 
H40C 3284 2574 9570 43 
______________________________________________________________________________
__ 
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 Table 5.  Torsion angles [°] for 1. 
________________________________________________________________  
O2-C1-C2-C3 102.0(6) 
O1-C1-C2-C3 -17.5(8) 
C1-C2-C3-C16 58.5(7) 
C1-C2-C3-C4 -60.5(7) 
C1-C2-C3-C8 179.6(6) 
C16-C3-C4-C5 159.5(7) 
C8-C3-C4-C5 30.9(9) 
C2-C3-C4-C5 -88.5(8) 
C3-C4-C5-O3 174.3(7) 
C3-C4-C5-C6 -5.3(11) 
C4-C5-C6-O4 170.4(7) 
O3-C5-C6-O4 -9.2(10) 
C4-C5-C6-C7 -16.8(11) 
O3-C5-C6-C7 163.5(6) 
O4-C6-C7-C8 -176.7(7) 
C5-C6-C7-C8 10.6(11) 
C6-C7-C8-C9 -160.3(7) 
C6-C7-C8-C3 17.0(11) 
C16-C3-C8-C7 -164.9(6) 
C4-C3-C8-C7 -36.6(9) 
C2-C3-C8-C7 81.1(8) 
C16-C3-C8-C9 12.5(9) 
C4-C3-C8-C9 140.7(6) 
C2-C3-C8-C9 -101.5(7) 
C7-C8-C9-C10 161.2(7) 
C3-C8-C9-C10 -16.1(10) 
C8-C9-C10-C11 10.0(11) 
C9-C10-C11-C12 173.2(7) 
C9-C10-C11-C16 -0.7(10) 
C16-C11-C12-C13 2.4(11) 
C10-C11-C12-C13 -171.3(6) 
C11-C12-C13-C14 4.3(11) 
C12-C13-C14-O5 173.0(7) 
C12-C13-C14-C15 -3.0(11) 
O5-C14-C15-O1 -3.2(10) 
C13-C14-C15-O1 173.2(6) 
O5-C14-C15-C16 178.6(6) 
C13-C14-C15-C16 -5.1(11) 
O1-C15-C16-C11 -166.6(6) 
C14-C15-C16-C11 11.7(11) 
O1-C15-C16-C3 0.4(10) 
C14-C15-C16-C3 178.6(6) 
C12-C11-C16-C15 -10.2(10) 
C10-C11-C16-C15 163.8(7) 
C12-C11-C16-C3 -176.2(7) 
C10-C11-C16-C3 -2.1(10) 
C4-C3-C16-C15 63.0(8) 
C8-C3-C16-C15 -170.1(6) 
C2-C3-C16-C15 -51.8(8) 
C4-C3-C16-C11 -130.8(7) 
C8-C3-C16-C11 -3.8(10) 
C2-C3-C16-C11 114.5(7) 
O7-C21-C22-C23 -100.2(6) 
O6-C21-C22-C23 19.8(8) 
C21-C22-C23-C28 -179.8(6) 
C21-C22-C23-C36 -60.3(7) 
C21-C22-C23-C24 59.3(7) 
C28-C23-C24-C25 -29.5(9) 
C36-C23-C24-C25 -159.0(6) 
C22-C23-C24-C25 89.7(7) 
C23-C24-C25-O8 -173.9(6) 
C23-C24-C25-C26 8.0(10) 
C24-C25-C26-O9 -174.9(7) 
O8-C25-C26-O9 6.8(10) 
C24-C25-C26-C27 12.9(10) 
O8-C25-C26-C27 -165.4(6) 
O9-C26-C27-C28 177.4(7) 
C25-C26-C27-C28 -10.6(10) 
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Table 5 Continued 
C26-C27-C28-C29 161.8(7) 
C26-C27-C28-C23 -12.5(11) 
C36-C23-C28-C27 161.3(6) 
C24-C23-C28-C27 31.4(9) 
C22-C23-C28-C27 -86.8(8) 
C36-C23-C28-C29 -13.1(9) 
C24-C23-C28-C29 -143.0(6) 
C22-C23-C28-C29 98.8(7) 
C27-C28-C29-C30 -155.7(7) 
C23-C28-C29-C30 18.5(11) 
C28-C29-C30-C31 -10.0(11) 
C29-C30-C31-C36 -3.4(10) 
C29-C30-C31-C32 -172.4(7) 
C36-C31-C32-C33 -0.2(11) 
C30-C31-C32-C33 168.7(7) 
C31-C32-C33-C34 -6.1(11) 
C32-C33-C34-C35 5.0(11) 
C32-C33-C34-O10 -173.5(6) 
C33-C34-C35-O6 -174.3(6) 
O10-C34-C35-O6 4.3(9) 
C33-C34-C35-C36 2.5(10) 
O10-C34-C35-C36 -178.9(6) 
C32-C31-C36-C35 7.7(10) 
C30-C31-C36-C35 -161.7(6) 
C32-C31-C36-C23 177.3(6) 
C30-C31-C36-C23 7.9(10) 
O6-C35-C36-C31 168.0(6) 
C34-C35-C36-C31 -8.9(11) 
O6-C35-C36-C23 -2.4(9) 
C34-C35-C36-C23 -179.2(6) 
C28-C23-C36-C31 0.2(10) 
C24-C23-C36-C31 129.0(7) 
C22-C23-C36-C31 -116.3(7) 
C28-C23-C36-C35 170.2(6) 
 
 
C24-C23-C36-C35 -61.1(8) 
C22-C23-C36-C35 53.7(7) 
C16-C15-O1-C1 47.5(8) 
C14-C15-O1-C1 -130.8(7) 
O2-C1-O1-C15 -156.4(5) 
C2-C1-O1-C15 -36.1(8) 
O1-C1-O2-C17 -64.3(7) 
C2-C1-O2-C17 172.7(5) 
C18-C17-O2-C1 -160.6(6) 
C4-C5-O3-C19 4.4(11) 
C6-C5-O3-C19 -176.0(6) 
C13-C14-O5-C20 -0.6(10) 
C15-C14-O5-C20 175.5(6) 
C34-C35-O6-C21 130.9(7) 
C36-C35-O6-C21 -45.9(8) 
O7-C21-O6-C35 155.6(5) 
C22-C21-O6-C35 34.6(8) 
O6-C21-O7-C37 65.2(7) 
C22-C21-O7-C37 -170.6(5) 
C38-C37-O7-C21 162.4(6) 
C24-C25-O8-C39 -5.8(10) 
C26-C25-O8-C39 172.4(6) 
C33-C34-O10-C40 3.5(10) 
C35-C34-O10-C40 -175.0(6)
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Cepharatine A (3) 
 
 
 
 
 
 
 
 
 
(6) (50 mg, 0.14 mmol) was added to a mixture of dioxane:water (1 mL: 0.05 mL) and 
amberlyst 15 (10 mg). The solution was allowed to stir overnight or until disappearance 
of starting material was observed by TLC. The amberlyst was removed from the solution 
by filtration. Methylamine Hydrochloride (500 mg, 7.4 mmol), pre-dissolved in 1.33 mL 
of water, was added and allowed to stir for five minutes. Three portions of 
triacetoxyborohydride (75 mg, 0.35) were added every 15 minutes. After three hours, the 
solvent was removed in vacuo and the amine was rudimentarily purified by preparative 
TLC (7:93 MeOH:CH2Cl2). The impure amine was then dissolved in water (2 mL) and 
1M HCl (.1 mL) was subsequently added. The solution was refluxed for 3 hours or until 
disappearance of starting material was observed by TLC. The solution was cooled and 
basified using saturated NaHCO3. The solvent was removed in vacuo and the compound 
was purified by preparative TLC (7:93 MeOH:CH2Cl2) to afford Cepharatine A (20 mg, 
42% over two steps) as a yellow solid. IR (thin film): 3424.7, 1642.8, 1562.0, 1482.5, 
1272.6, 1075.61  1H NMR (400 MHz, CDCl3) δ 6.78 (2H, s), 6.71 (1H, d, J = 9.6), 6.31 
(1H, d, J = 9.2), 6.13 (1H, s), 3.95 (3H, s), 2.71 (1H, m), 2.67 (2H, m), 2.26 (4H, s), 1.40 
(1H, s), 1.37 (1H, s). 13C NMR (100 MHz, CDCl3): 193.9, 161.5, 148.1, 144.4, 136.1, 
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125.6, 125.4, 124.0, 123.4, 121.3, 108.7, 83.3, 56.1, 46.6, 44.3, 43.4, 36.2, 31.3. HRMS 
calcd. for C18H20NO4: 314.13868 (M+Na) found 314.1386 
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